美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Rxi Pharmaceuticals Corp

0.3302

0.0000

成交量：- -

成交額：- -

市值：144.51萬

市盈率：-0.11

高：0.3302

開：0.3302

低：0.3302

收：0.3302

52周最高：7.70

52周最低：0.3100

股本：437.63萬

流通股本：230.08萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-3.0991

每股收益(LYR):-5.5152

淨資產收益率：--

總資產收益率：--

市淨率：0.44

市盈率(LYR):-0.06

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Rxi Pharmaceuticals Corp

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.rxipharma.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Rxi Pharmaceuticals Corporation是一家生物技術公司，基於公司專有的新一代核糖核酸干擾(RNAi)平台專註於發現、開發和商業化創新療法。由於這些療法得“沉默”能力,或者說是其下調能力,病態情況下的特定基因可以被分析的更為清楚，所以基於RNAi平台的療法更有說服力的。2011年9月8日之前,該公司的業務由其非操作部門Galena Biopharma公司（該公司的前母公司）來完成。公司成立於特拉華州，作為Galena 的全資子公司。2011年9月8日開始，其計劃並準備與Galena脫離。2012年4月27日這一計劃得以完成。至此之後,公司作為一個獨立的上市公司運營。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/RXII/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RXII","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RXII\",,,,,undefined,":{"symbol":"RXII","market":"US","secType":"STK","nameCN":"Rxi Pharmaceuticals Corp","latestPrice":0.3302,"timestamp":1542401999999,"preClose":0.3302,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":2300823,"shares":4376322,"eps":-3.099079,"marketStatus":"休市中","change":0,"latestTime":"11-16 15:59:59 EST","open":0.3302,"high":0.3302,"low":0.3302,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.099079,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"symbolChange":{"newSymbol":"PHIO","executeDate":"2018-11-19"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.3302,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RXII\",,,,,undefined,":{"symbol":"RXII","floatShares":2300823,"roa":"--","roe":"--","lyrEps":-5.515215,"shares":4376322,"dividePrice":0,"high":0.3302,"amplitude":0,"preClose":0.3302,"low":0.3302,"week52Low":0.31,"pbRate":"0.44","week52High":7.7,"institutionHeld":0,"latestPrice":0.3302,"eps":-3.099079,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.099079,"open":0.3302},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RXII\",params:#limit:5,,,undefined,":[{"date":"2018-11-19","symbol":"RXII","newSymbol":"PHIO","type":"symbolChange","dateTimestamp":1542603600000},{"market":"US","date":"2018-11-14","symbol":"RXII","fiscalQuarterEnding":"2018/09","expectedEps":-0.45,"name":null,"time":"盤後","type":"earning","dateTimestamp":1542171600000,"reportTimeType":"post","actualEps":-0.34},{"market":"US","date":"2018-08-14","symbol":"RXII","fiscalQuarterEnding":"2018/06","expectedEps":-0.59,"name":null,"time":"盤後","type":"earning","dateTimestamp":1534219200000,"reportTimeType":"post","actualEps":-0.46},{"market":"US","date":"2018-05-10","symbol":"RXII","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1525924800000,"reportTimeType":"post","actualEps":-0.9},{"market":"US","date":"2018-03-26","symbol":"RXII","fiscalQuarterEnding":"2017/12","expectedEps":-0.96,"name":null,"time":"","type":"earning","dateTimestamp":1522036800000,"reportTimeType":"","actualEps":-0.84}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RXII\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RXII\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.rxipharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Rxi Pharmaceuticals Corporation是一家生物技術公司，基於公司專有的新一代核糖核酸干擾(RNAi)平台專註於發現、開發和商業化創新療法。由於這些療法得“沉默”能力,或者說是其下調能力,病態情況下的特定基因可以被分析的更為清楚，所以基於RNAi平台的療法更有說服力的。2011年9月8日之前,該公司的業務由其非操作部門Galena Biopharma公司（該公司的前母公司）來完成。公司成立於特拉華州，作為Galena 的全資子公司。2011年9月8日開始，其計劃並準備與Galena脫離。2012年4月27日這一計劃得以完成。至此之後,公司作為一個獨立的上市公司運營。","exchange":"NASDAQ","name":"Rxi Pharmaceuticals Corp","nameEN":"RXi Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"RXII\",market:\"US\",,,undefined,":null}}